Ablynx closes €25mm Series B round
Executive Summary
Ablynx NV, a company focused on the discovery and development of a new class of therapeutic antibodies called nanobodies, raised €25mm ($30.3mm) with its Series B financing of preferred stock led by Alta Partners. New investor Abingworth Management participated along with existing shareholders GIMV, Biotech Fund Flanders (managed by GIMV), Sofinnova Partners, and Gilde.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice